ProCE Banner Activity

CE / CME

Clinical Crossroads: Navigating MDD Treatment Challenges Through Real-world Cases

Video

On-demand webcast of expert faculty presentation and case discussion on managing patients with MDD, including strategies for navigating treatment challenges as seen in real-world cases. 

Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Psychologists: 1.00 APA CE Credit

Social Workers: 1.00 ASWB ACE CE Credit

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: September 19, 2024

Expiration: September 18, 2025

Continue Activity

Share

Faculty

Greg W. Mattingly

Greg W. Mattingly, MD

Associate Clinical Professor, Washington University
President, Midwest Research Group
President, American Professional Society of ADHD and Related Disorders
St Louis, Missouri

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc. and Intra-Cellular Therapies, Inc.

AbbVie Inc.

Intra-Cellular Therapies, Inc.

Target Audience

This program is intended for healthcare professionals caring for patients with major depressive disorder, including physicians (psychiatrists and family medicine/primary care), nurse practitioners, physician associates, registered nurses, pharmacists, social workers, and psychologists. 

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with depression.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Summarize criteria that determine when to switch or augment medications in MDD, based on best practices

  • Interpret the emerging evidence for the use of antipsychotics in the treatment of MDD

  • Select an evidence-based augmentation agent for a patient with MDD

  • Differentiate augmentation treatment options in MDD based on pharmacology

  • Construct an individualized treatment plan for a patient with MDD, with consideration for patient and medication characteristics

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Greg W. Mattingly, MD

Associate Clinical Professor, Washington University
President, Midwest Research Group
President, American Professional Society of ADHD and Related Disorders
St Louis, Missouri

Greg W. Mattingly, MD: consultant/advisor/speaker: AbbVie, Acadia, Akilli, Alkermes, Angelini, Axsome, Aytu, Biogen, Boehringer Ingelheim, Cerevel, Corium, Eisai, Intracellular, Ironshore, Janssen, Liva Nova, Lumos Labs, Lundbeck, Manus, Neurocrine, Noven, Otsuka, Redax, Relmada, Revibe, Roche, Sage, Sirona, Sky Therapeutics, Sunovion, Supernus, Takeda, Teva, Tris; researcher: AbbVie, Acadia, Alkermes, Akilli, Alto Therapeutics, Autobahn, Avanir, Axsome, Boehringer Ingelheim, Cingulate, Click Therapeutics, Compass, Corium, Emalex, Idorsida, Intracellular, Janssen, Karuna, Lumos Labs, Medgenics, Neumora, Neurocrine, NLS-1 Pharma, Redax, Relmada, Roche, Sage, Sirtsei, Sumitomo, Sunovion, Supernus, Takeda, Teva.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose except Michael Asbach, DMSc, PA-C, Psych-CAQ as noted below:​

Michael Asbach, DMSc, PA-C, Psych-CAQ: consultant/advisor/speaker: AbbVie, Avanir, Biogen, Intracellular, Janssen, Karuna, Neurocrine, Otsuka, Teva.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 19, 2024, through September 18, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacotherapy credit.  

Continuing Pharmacy Education

CCO designates this continuing education activity for 1 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-24-244-H01-P 

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until September 18, 2025. PAs should only claim credit commensurate with the extent of their participation.

Social Work Continuing Education

As a Jointly Accredited Organization, Clinical Care Options, LLC is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1 clinical continuing education credits.

Psychologist Continuing Education

 

Continuing education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

This activity offers 1 continuing education credits for psychologists.

ABMS Approval Statement

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory,  Clinical Crossroads: Navigating MDD Treatment Challenges Through Real-World Cases has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards: 

ABMS Lifelong Learning CME Activity
Psychiatry and Neurology​

CME Passport

662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.